Imgatuzumab clinical trials
Also written RO5083945.
- studies test it
- 5
- open now
- 0
- in phase 3
- 0
- first study started
- 2008
How each study uses imgatuzumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
5 studies that test it; most in 2008 (1)
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 0
Hoffmann-La Roche (4) · Pega-One S.A.S. (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses imgatuzumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal CancerCompletedPhase 2Hoffmann-La RocheNCT01326000Written as RO5083945
- Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell CarcinomaWithdrawnPhase 2Pega-One S.A.S.NCT04985825Written as Imgatuzumab
- A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.CompletedPhase 1Hoffmann-La RocheNCT00721266Written as RO5083945
- A Study of Pharmacodynamics of RO5083945 in Patients With Head and Neck Squamous Cell CarcinomaCompletedPhase 1Hoffmann-La RocheNCT01046266Written as RO5083945
- A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung CancerCompletedPhase 2Hoffmann-La RocheNCT01185847Written as RO5083945
Given beside what is tested · 1 — imgatuzumab is usual care or a partner of the new treatment
Codes
What other systems call imgatuzumab · ClinicalTrials.gg INT005968
- MeSH (NLM) C569293imgatuzumabOne source NLM
- UNII (FDA) V77J4WJF9ZIMGATUZUMABConfirmed FDA, NLM, Wikidata
- Wikidata Q6003939ImgatuzumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C78838ImgatuzumabOne source FDA
- DrugBank DB14884One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C569293 | imgatuzumab | One source NLM |
| UNII (FDA) | V77J4WJF9Z | IMGATUZUMAB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q6003939 | Imgatuzumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C78838 | Imgatuzumab | One source FDA |
| DrugBank | DB14884 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.